Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Review ArticleReview

International Union of Pharmacology. XXIV. Current Status of the Nomenclature and Properties of P2X Receptors and Their Subunits

Baljit S. Khakh, Geoffrey Burnstock, Charles Kennedy, Brian F. King, R. Alan North, Philippe Séguéla, Mark Voigt and Patrick P. A. Humphrey
Pharmacological Reviews March 2001, 53 (1) 107-118;
Baljit S. Khakh
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey Burnstock
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Kennedy
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian F. King
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Alan North
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philippe Séguéla
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Voigt
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick P. A. Humphrey
1 2 3 4 5 6 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

ATP acts as a humoral mediator to control cell function extracellularly. The receptors that mediate the actions of ATP belong to two classes, the metabotropic P2Y receptors and the transmitter-gated, ion channel P2X receptors. This review describes the structure, distribution, function, and ligand recognition characteristics of P2X receptors, which comprise seven distinct subunits that can function as both homo- and hetero- polymers. The pharmacology of P2X receptors is complicated by marked differences between species orthologues. The current nomenclature is based largely on recombinant receptor studies and detailed knowledge of endogenous P2X receptors in native tissues is limited because of lack of good selective agonists and antagonists for each receptor type.

I. Introduction

ATP is probably found in every living cell, representing the major energy source among organic phosphate compounds utilized in metabolism (Hinkle and McCarty, 1978; Gibson, 1982). Perhaps because of this, organisms have evolved specialized cell surface receptors to detect ATP when it is released extracellularly. These receptors have been collectively called P2 receptors because their endogenous agonist, ATP, is a purine and they are distinct from P1 receptors, which are activated by the other equally ubiquitous, endogenous purine, adenosine (Burnstock and Kennedy, 1985; Fredholm et al., 1994). In turn, P2 receptors can be subdivided into those that are of the ligand-gated ion channel-type, namely P2X receptors, and those that are G protein-coupled, called P2Y receptors (Burnstock and Kennedy, 1985; Fredholm et al., 1994). This review covers the pharmacological properties of recombinant and native P2X receptor types and their nomenclature. Mammalian P2X receptors belong to a family of at least seven proteins (P2X1–P2X7) that are found throughout the body, are abundantly expressed in the nervous system, underlie fast purinergic synaptic transmission, and are involved in diseases of the nervous system and periphery. This perspective reveals the pharmacological basis by which distinct P2X receptors can be discriminated.

II. Overall P2X Subunit Topology

Seven P2X subunits (P2X1–P2X7) define the simplest transmitter-gated ion channel family. Their identities range between 26 to 47%, and each subunit is between 379 and 595 amino acids in length, P2X6 being the smallest and P2X7 the longest (see Fig.1). In terms of numbers, the P2X family is comparable in size to other transmitter-gated cation channels, and 11 different P2X receptor subunit combinations have been studied, but many more heteromeric receptors are possible than have been electrophysiologically characterized. P2X subunits have two transmembrane domains of sufficient length to cross the plasma membrane, placing most of the protein extracellularly (see Fig. 1;Brake et al., 1994; Valera et al., 1994; Newbolt et al., 1998; Torres et al., 1998a; Rettinger et al., 2000). The extracellular loop contains the ATP binding site (Ennion et al., 2000; Jiang et al., 2000) and sites for antagonists and modulators (Buell et al., 1996a;Garcia-Guzman et al., 1997; Clarke et al., 2000). Substituted cysteine accessibility mutagenesis has been used extensively to identify residues that line the channel walls (Rassendren et al., 1997a; Egan et al., 1998). In brief, transmembrane domain 2 (TM2) lines the pore and the narrowest part of the channel pore is probably near a conserved glycine (at position 342 of P2X2), about half way through TM2 (Egan et al., 1998).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Topology of, and similarity between, P2X receptor subunits. a, diagrammatic representation of presently understood P2X subunit topology (see text for details); b, relations among the seven rat P2X subunits. The alignment was made using default parameters in DNASTAR (http://www.dnastar.com/). The protein sequences were retrieved from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/Entrez/) and had the following accession numbers: P2X1 NP_037129, P2X2 s50859, P2X3 P49654, P2X4 P51577, P2X5 P51578, P2X6 P51579, P2X7 NP_062129. c, percent identity between the seven rat P2X subunits determined from alignments performed in DNASTAR.

Site-directed mutagenesis experiments suggest an important role for residues in the C terminal tail of rat P2X2channels in determining the rate of desensitization (King et al., 1996;Brandle et al., 1997; Simon et al., 1997; Koshimizu et al., 1998, 1999;Smith et al., 1999). The C terminal tails are not the sole determinants of desensitization, and other domains of P2X channels may also contribute (Werner et al., 1996; Boué-Grabot et al., 2000), as one may expect for allosteric proteins.

P2X receptors, like other ion channels, are oligomeric proteins composed of more than one subunit per functional receptor. The number of subunits per receptor—the receptor stoichiometry—is at present unclear; as few as three or four subunits or as many as six may contribute to the receptor, but decisive experiments are required (Kim et al., 1997; Nicke et al., 1998; Stoop et al., 1999). The evidence in favor of a trimer as a minimal unit for P2X receptors is supported by electrophysiological studies (Stoop et al., 1999).

III. Electrophysiological Properties of P2X Receptors

All P2X receptors are cation-selective channels with almost equal permeability to Na+, K+, and significant permeability to Ca2+ (Evans et al., 1996). Quantitative experiments on Ca2+permeability are usually performed in two ways: 1) the fraction of the total agonist-evoked current carried by Ca2+ is determined in physiological solutions, or 2) the permeability of Ca2+ relative to Na+ is measured using reversal potentials. Both are valid approaches and have been used for P2X channels (see Table 1). For example, native superior cervical ganglion (SCG2) neuron P2X receptors are most like homomeric P2X2 receptors and carry a fractional Ca2+ current of ∼6.5% in physiological solutions (Rogers and Dani, 1995; Rogers et al., 1997). This is higher than the fractional Ca2+current carried by nicotinic, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and kainate receptors (fractional currents of ∼4.5, 4, and 2%, respectively) but lower than that ofN-methyl-d-aspartate receptors, which carry a fractional calcium current of ∼12%. Heterologously expressed P2X1, P2X2, P2X3, P2X4, P2X2/3, and P2X1/5receptors are all permeable to Ca2+ (see Table1). Ca2+ permeation through P2X receptors is probably an important component of the physiological responses mediated by P2X receptors in vivo, and perhaps aberrant Ca2+ entry through P2X receptors can also contribute to P2X receptor-associated pathology. However, it is notable that P2X2 single channels do not carry a significant Ca2+ current (Ding and Sachs, 1999a), whereas the macroscopic P2X2 channel current does (see Table 1).

View this table:
  • View inline
  • View popup
Table 1

Known Ca2+ permeabilities of P2X receptors in relation to some other transmitter-gated cation channels

Calcium ions do have other actions at P2X receptors. Ca2+ blocks and modulates ATP-evoked currents at endogenously and heterologously expressed P2X receptors (Nakazawa and Hess, 1993; Evans et al., 1996; Surprenant et al., 1996; Virginio et al., 1997, 1998a, 1999a,b; Cook et al., 1998; Ding and Sachs, 1999b,2000; Khakh et al., 1999a). The amino acid residue(s) involved in Ca2+ permeation are probably part of the pore lining segments (Rassendren et al., 1997a; Egan et al., 1998), but the molecular players in Ca2+ block and modulation of P2X receptors are unknown, and may include residues in the extracellular loop.

Some P2X receptors are also permeable to large organic cations. It has been known for some time that P2Z receptors (P2X7) display interesting permeation properties (Cockcroft and Gomperts, 1979; Nuttle and Dubyak, 1994; Surprenant et al., 1996). Ionic selectivity has generally been viewed as fixed, with good evidence for many ion channels (Fox, 1987), but one interesting difference between P2X receptors and other transmitter-gated cation channels is the time-dependent decrease in ionic selectivity for P2X receptors (Surprenant et al., 1996). In fact the change in ionic selectivity occurs with P2X2, P2X4, and P2X7 receptors, as measured electrophysiologically and with dye uptake studies (Surprenant et al., 1996, 2000; Khakh and Lester, 1999; Khakh et al., 1999b, 2000b; Virginio et al., 1999a,b), as well as with native P2X receptors studied in the same way. The possible mechanisms for ion-selectivity changes for different ion channels have recently been discussed (Khakh and Lester, 1999).

IV. Functional Properties of Homomeric Receptors

The pharmacological properties of recombinant homomeric P2X receptors have recently been reviewed (Khakh et al., 2000a; North and Surprenant, 2000; see Table 2). All seven P2X subunits form functional receptors when expressed alone in various expression systems, but homomeric P2X6 receptors have been particularly hard to study because of poor and erratic expression (Collo et al., 1996; Le et al., 1998a; Khakh et al., 1999b;Torres et al., 1999; King et al., 2000). Early studies of homomeric P2X receptors identified clear pharmacological distinctions between them, which endure and are now supported by further data. However, distinctions between homomeric P2X receptors based on differences in desensitization are less clear, especially in multicellular preparations and in vivo. We argue against the use of desensitization criteria to define P2X receptor because 1) the underlying mechanisms are poorly understood, 2) channel sub-states may have different kinetics, 3) sub-states may be subject to differential post-translational modification, and 4) desensitization is difficult to measure and quantify over a time-scale of hundreds of milliseconds in multicellular preparations. One initial observation, the finding that P2X1 and P2X3 receptors desensitize much more rapidly (within ∼1 s in all expression systems) than other homomeric P2X receptors, has been exploited with success to identify heteromeric receptors in single cells (Lewis et al., 1995;Torres et al., 1998b; Haines et al., 1999; Le et al., 1999). Sensitivity to the agonist αβ-meATP continues to be an important tool for studying P2X receptors in single cells. Unlike ATP, αβ-meATP is resistant to enzymatic degradation (Humphrey et al., 1995; Kennedy and Leff, 1995) and thus can be used to identify P2X receptors in multicellular preparations including whole animals (Humphrey et al., 1995; Khakh et al., 1995b; Bland-Ward and Humphrey, 1997; McQueen et al., 1998; Kirkup et al., 1999; Tsuda et al., 1999). Weak sensitivity to the ATP receptor antagonists suramin and PPADS2 are diagnostic features of homomeric rat P2X4 receptors, although important species differences exist (Bo et al., 1995; Buell et al., 1996a;Séguéla et al., 1996; Soto et al., 1996a; Le et al., 1998a). Rat P2X4 receptors are potentiated by ivermectin (Khakh et al., 1999b), but ivermectin also modulates γ-aminobutyric acid and nicotinic receptors (Krusek and Zemkova, 1994; Krause et al., 1998).

View this table:
  • View inline
  • View popup
Table 2

Functional properties of recombinant homomeric P2X receptors

In the absence of potent radioligands, the few binding studies reported have utilized radiolabeled ATP or its structural analogs. However complications due to metabolism have necessitated that such studies be carried out at room temperature or in the absence of divalent cations so comparison with functional data is confounded. Nevertheless it has been possible to label recombinant P2X1-P2X4 receptors using [35S]ATPγS and [3H]αβ-meATP (Bo et al., 1992; Michel et al., 1996b, 1997). Although the affinity estimates for agonists are much higher than expected from functional studies (see Humphrey et al., 1998; Chessell et al., 2001), studies with antagonists have provided affinity estimates that are similar in both binding and functional studies (Khakh et al. 1994; Michel et al., 1997). The selective affinity of β,γ-methylene-l-ATP was first detected in binding studies, and its selectivity as an agonist for P2X1 relative to P2X3receptors confirmed in functional studies (Trezise et al., 1995; Rae et al., 1998). Radioligand binding studies have also provided evidence for allosteric regulation of the P2X4 receptor by cibacron blue, which correlated with potentiation of responses in functional studies on the rat recombinant receptor (Michel et al., 1997; Miller et al., 1998).

A long-awaited development has been the discovery of high-affinity (nanomolar) antagonists. TNP-ATP, TNP-ADP, and TNP-AMP block P2X1, P2X3, and P2X2/3 receptors with 1000-fold higher affinity than at other homomeric P2X receptors (Thomas et al., 1998; Virginio et al., 1998b). Together with IP5I, which blocks P2X1 and P2X3 receptors, but not P2X2 and P2X2/3receptors (King et al., 1999; Dunn et al., 2000), they are useful in vitro tools because their use allows direct demonstration of P2X receptor heterogeneity in sensory neurons (Burgard et al., 1999; Grubb and Evans, 1999; Dunn et al., 2000; Patel et al., 2001). However, the use of TNP-ATP in multicellular preparations is probably quite limited by its susceptibility to enzymatic breakdown (Lewis et al., 1998). Ecto-ATPases have an impressive ability to rapidly metabolize nucleotides [within 200 ms in a hippocampal brain slice (Dunwiddie et al., 1997)], but we expect that ecto-ATPases are not a complicating factor under conditions where agonists have been applied rapidly (Evans and Kennedy, 1994; Zimmermann, 1994; Humphrey et al., 1995; Kennedy and Leff, 1995; Khakh et al., 1995b; Zimmermann and Braun, 1996). Considerable effort has been devoted to defining the ligand recognition characteristics of each of the seven homomeric P2X channels using rapid application of agonists and antagonists (Table 2). The properties of some of these presumed homomeric channels are very similar to P2X channels that have been identified in native cell types, suggesting that native cell types may express homomeric P2X channels as well (compare Table 2 and Table 4).

View this table:
  • View inline
  • View popup
Table 4

Functional properties of some native P2X receptors

From the original papers, we report the antagonist IC50 values reported for various homomeric P2X receptors (Table 2). These data present a general view of the differences between receptor types, but IC50values are without any quantitative definition, and cannot be equated with the desired measurement of affinity. IC50values are often used in radioligand binding experiments, but in functional experiments, their use is more limited. For example, even if one assumes competition between agonist and antagonist for one binding site, we expect the antagonist IC50 to change with agonist concentration. This makes it problematic to compare antagonist IC50 values between studies, because many investigators have used different agonist concentrations. Moreover, even at any one agonist concentration, assuming competition, the antagonist IC50 is without quantitative or mechanistic definition, because unlike with radioligand binding experiments, in functional studies there are multiple steps, subsequent to binding, that lead to the final parameter—the open state (Colquhoun, 1998; Grosman et al., 2000). These problems are even more of a concern because many ATP receptor antagonists are clearly not competitive, e.g., PPADS (Li, 2000). It should also be emphasized that suramin is a poor antagonist of low potency and questionable selectivity, even blocking glutamate channels (Nakazawa et al., 1995). Suramin also inhibits ecto-ATPases, like other antagonists such as PPADS, which complicates assessment of antagonist potency against hydrolyzable agonists in isolated tissue studies (see Humphrey et al., 1995). Better antagonists are eagerly awaited; in the meantime IC50 values should be treated with caution for all the various reasons discussed, although the general trends are informative (compare Tables 2 and 4). However, the data is further confounded by interspecies differences in agonist and antagonist potencies, notably at P2X4 and P2X7 receptors (Chessell et al., 1998a,b; Hibell et al., 2000; Jones et al., 2000).

A. P2X1

The rP2X1 subunit cDNA was isolated by expression cloning from vas deferens smooth muscle (Valera et al., 1994), and P2X1 mRNA and protein are abundantly expressed in smooth muscle preparations (Valera et al., 1994; Bo et al., 1998; Chan et al., 1998; Nori et al., 1998). These observations extend electrophysiological studies demonstrating ATP-activated currents in smooth muscle myocytes (Suzuki, 1985; Benham et al., 1987;Benham and Tsien, 1987; Nakazawa and Matsuki, 1987; Friel, 1988; Friel and Bean, 1988; Benham, 1989; Honore et al., 1989; Inoue and Brading, 1990). The properties of P2X receptors expressed in smooth muscle preparations are most like those of recombinant P2X1 receptors. This suggests that homomeric P2X1 receptors constitute native P2X receptors in smooth muscle preparations (Evans and Kennedy, 1994; Khakh et al., 1995b; Lewis et al., 1998; Lewis and Evans, 2000). Evidence to confirm that vas deferens smooth muscle myocytes express P2X1 receptors was obtained by ablation of the P2X1 gene in mice; predictably there were no ATP-evoked responses in vasa deferentia of these mice (Mulryan et al., 2000). P2X1 receptors are present on smooth muscle cells of blood vessels where they can be activated by neuronally released ATP, and mediate blood vessel constriction (Evans and Surprenant, 1992). In a surprise, but preliminary result, blood pressure was normal in mice lacking P2X1receptors; one possibility is that P2X1 receptors are not the sole vascular P2X receptors (Nori et al., 1998; Lewis and Evans, 2000). Other explanations including developmental compensation are possible and need to be systematically addressed. P2X1 receptors also exist in the immature rat brain (Kidd et al., 1995), cerebellum (Loesch and Burnstock, 1998), dorsal horn spinal neurons (Vulchanova et al., 1996), and platelets (Clifford et al., 1998; Scase et al., 1998).

B. P2X2

Electrophysiological studies reveal that P2X receptors that have properties most similar to homomeric P2X2receptors, are widely expressed in the nervous system. For example, myenteric neurons (Zhou and Galligan, 1996), rat and guinea pig SCG neurons neurons (Boehm, 1999; Khakh et al., 1995a; Surprenant et al., 1995; Zhong et al., 2000a), mouse pelvic neurons (Zhong et al., 1998), mouse and rat celiac neurons (Zhong et al., 2000b), guinea pig chromaffin cells (Liu et al., 1999), guinea pig cochlea (Housley et al., 1999; Chen et al., 2000), dorsal horn neurons (Hugel and Schlichter, 2000), auditory neurons (Salih et al., 1999), cerebellar Purkinje neurons (Garcia-Lecea et al., 1999), possibly retinal ganglion neurons (Taschenberger et al., 1999), rat SCG nerve terminals (Boehm, 1999), and neurohypophysial terminals (Troadec et al., 1998) all express functional P2X2-like receptors. Although these studies suggest a major role for homomeric P2X2 receptors in these cell types, they do not prove it. Heteromeric assemblies in which P2X2receptors dominate or coexpression of more than one type of P2X receptor cannot be fully dismissed in many cases. P2X2 subunit mRNA is widely expressed in the CNS (Collo et al., 1996) raising the possibility that more native homomeric P2X2 receptors exist. Recent work on the P2X5 mRNA rich trigeminal mesencephalic nucleus neurons (Collo et al., 1996; Cook et al., 1997; Khakh et al., 1997, 1999b; Patel et al., 2001) shows that they express functional P2X receptors that may comprise P2X2and P2X5 receptor subunits.

C. P2X3

Early observations of ATP-evoked currents in sensory neuronal soma (Jahr and Jessell, 1983; Krishtal et al., 1983, 1988a,b), and axons (Trezise et al., 1994a,b) were important for the general appreciation that ATP could directly activate receptors with integral ion pores in sensory neurons. Homomeric P2X3 receptors, or heteromeric P2X2/3 receptors, mediate a major component of these sensory neuron ATP responses. The evidence is based on gene cloning, electrophysiology, in situ hybridization, and immunocytochemistry (Chen et al., 1995; Lewis et al., 1995; Collo et al., 1996; Robertson et al., 1996; Vulchanova et al., 1996, 1997;Virginio et al., 1998a,b; Grubb and Evans, 1999). There is increasing support for the hypothesis that ATP, acting via P2X3 receptors, is involved in certain types of pain; we do not discuss this topic further because it has been extensively reviewed (Burnstock, 1996, 2000; McCleskey and Gold, 1999).

D. P2X4

The P2X4 subunit is found extensively in the CNS and perhaps is a major target for ATP released in CNS synapses. The ATP receptor antagonists suramin and PPADS (see Tables 1 and 2) have conflictingly been shown to be ineffective or weak antagonists at the rP2X4 receptor (Buell et al., 1996a; Soto et al., 1996a), to completely block ATP-evoked currents (Séguéla et al., 1996), or to potentiate them (Bo et al., 1995). PPADS is notably more effective as an antagonist at the human P2X4and mouse P2X4 channels than at the rat isoform (Garcia-Guzman et al., 1997; Jones et al., 2000). Recent studies demonstrate that ivermectin is a selective allosteric modulator of rat P2X4 channels expressed in Xenopusoocytes (EC50 = 250 nM), although all possible homomeric or heteromeric P2X subunit assemblies were not tested. A lack of block by suramin and potentiation by ivermectin may be a useful diagnostic feature of rat P2X4 channels (Khakh et al., 1999b). Rat P2X4 channel currents are potentiated by cibacron blue between 3 and 30 μM (Miller et al., 1998), but another study shows that cibacron blue blocks them with an IC50 of 128 μM (Garcia-Guzman et al., 1997), with no obvious potentiation being reported. Mouse P2X4 channel currents are potentiated by suramin, reactive blue2, and PPADS; concentrations of PPADS >3 μM may also block mouse P2X4 receptor currents (Townsend-Nicholson et al., 1999).

Rat P2X4 subunits form a heteromeric receptor with P2X6 subunits when coexpressed inXenopus oocytes and HEK293 cells (Le et al., 1998a), but to date there is no evidence for an equivalent native receptor. The splice variant mouse P2X4(a) expresses poorly on its own but may contribute in a heteromeric assembly with full-length mouse P2X4 receptor (Townsend-Nicholson et al., 1999). Native P2X receptors in the brain may be like P2X4 receptors, largely because P2X4 receptors are abundantly expressed in the brain (Bo et al., 1995; Collo et al., 1996; Soto et al., 1996a; Le et al., 1998b). However, in a preliminary investigation the properties of P2X receptors in the hippocampus CA1 region (Proctor and Dunwiddie, 1998; Khakh et al., 1999b; Proctor et al., 1999) are unlike P2X4 receptors, despite the fact that the most abundant mRNA species is P2X4.

E. P2X5

The P2X5 subunit mRNA is present in some parts of the brain, heart, spinal cord, and adrenal medulla, as well as thymus and lymphocytes (Collo et al., 1996; Garcia-Guzman et al., 1996;Le et al., 1997). When heterologously expressed as a homomer, minimal desensitization is observed with the rat receptor, but the channel currents are of small amplitude (Collo et al., 1996). The full sequence of the human P2X5 receptor has yet to be confirmed (Le et al., 1997). The recently identified P2X subunit from chick skeletal muscle was tentatively called the chick P2X8 subunit (Bo et al., 2000), because 1) it has 59% sequence homology to rat and human P2X5subunits, and 2) it has unique functional properties. But, further sequence analysis indicates it is a species homolog of P2X5. There is clear evidence for a P2X1/5 heteromeric receptor with properties distinct from P2X1 and P2X5receptors (Torres et al., 1998b; Haines et al., 1999; Le et al., 1999). The trigeminal mesencephalic nucleus is rich in P2X5 mRNA and electrophysiological recordings show that neurons from this nucleus express two populations of functional P2X channels, one of which is most like homomeric P2X5 receptors (Cook et al., 1997; Khakh et al., 1997; Patel et al., 2001). A second population of P2X receptors contain the P2X2 subunit (Patel et al., 2001).

F. P2X6

In initial studies, when the P2X6 subunit was heterologously expressed as a homomer, ATP-evoked currents were observed in only a very small proportion of HEK293 cells (Collo et al., 1996). Currently the emerging picture is that homomeric P2X6 channels are not readily expressed inXenopus oocytes or mammalian transfected cells (Collo et al., 1996; Le et al., 1998a; Khakh et al., 1999b; Torres et al., 1999;King et al., 2000; North and Surprenant, 2000).

G. P2X7

Recombinant P2X7 receptors are weakly activated by ATP (EC50 in the 100 μM range), whereas other P2X channels respond to ATP with an EC50 in the low micromolar range. Various compounds block P2X7 receptors with high affinity: calmidazolium appears to block only the initial Na+ current through P2X7receptors and not the secondary “pore” that is permeable to large molecules such as YO-PRO1 and ethidium bromide (Virginio et al., 1997). KN62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl]-4-phenylpiperazine) and KN04 (N-[1-[N-methyl-p-(5-isoquinolinesulfonyl)benzyl]-2-(4-phenylpiperazine) ethyl]-5-isoquinolinesulfonamide) potently block human P2X7 channels in the tens of nanomolar concentration range, but not rat P2X7 receptors (Chessell et al., 1998a,b; Humphreys et al., 1998). KN62 is a blocker of CAM (Ca2+/calmodulin-dependent protein) kinase II, but the block of human P2X7 receptors does not involve this enzyme, rather KN62 probably binds to unique residues in the extracellular loop of human P2X7 receptors (Humphreys et al., 1998). P2X7 receptor function is potently modulated by cations, and this must be considered when comparing functional data between different studies.

V. Functional Properties of Heteromeric Receptors

Distinct P2X subunits assemble to form at least 11 different heteromeric receptors. Often native cell types express multiple P2X subunit mRNA transcripts and multiple P2X subunits (Kidd et al., 1995;Collo et al., 1996; Vulchanova et al., 1996, 1997). Recently, we have come to learn of the prevalence and mechanisms that determine P2X subunit heteromerization (Torres et al., 1999), and these studies are instructive for studies of native systems. A few points warrant attention. P2X6 subunits form heteromeric but not homomeric channels (Torres et al., 1999). P2X7subunits form only homomeric channels. Fewer heteromeric assemblies have been detected than are theoretically possible, even with pairwise comparisons, and this implies some specificity in the partnerships that P2X subunits make. From biochemical studies, 11 different P2X receptors can be formed from the seven known subunits in pairwise comparisons (Torres et al., 1999), and it is important to determine their functional properties (see Table 3). We do not yet understand how many subunits are required in each heteromer, which ones dominate, or if a greater number of heteromers can be formed if cells are given the choice to express more than any two P2X subunits, as may be the case in the spinal cord (Hugel and Schlichter, 2000). The heteromer formed between P2X2 and P2X3 subunits is perhaps the best understood; support for it has come from studies of native P2X receptors in sensory neurons (Lewis et al., 1995; Cook et al., 1997; Radford et al., 1997), biochemical studies on P2X2 and P2X3 subunits (Radford et al., 1997; Vulchanova et al., 1997; Torres et al., 1999), and electrophysiology on cells that coexpress P2X2 and P2X3subunits (Lewis et al., 1995; Radford et al., 1997). Similar approaches have been used to show that P2X4 and P2X6 subunits form a heteromer (Le et al., 1998a), as do P2X2 and P2X6subunits (King et al., 2000). A P2X1/5 heteromer has also been identified on the basis of similar experiments (Haines et al., 1999; Le et al., 1999; Torres et al., 1998b, 1999), and such a channel may exist in discrete areas in the spinal cord and in the gut (Surprenant et al., 2000). Although P2X4 subunit messenger RNA and protein is widely expressed in the CNS and homomeric P2X4 receptors are readily formed in heterologous expression systems (Bo et al., 1995; Buell et al., 1996a; Collo et al., 1996; Séguéla et al., 1996; Soto et al., 1996a; Le et al., 1998b), to date there is no decisive evidence for native P2X4-like channels in the CNS. Instead, in areas that abundantly express P2X4 mRNA the functional properties of native P2X receptors are most like other homomeric P2X receptors, a mixture of P2X receptors or possibly novel heteromers (Nabekura et al., 1995; Proctor and Dunwiddie, 1998; Khakh et al., 1999b; Proctor et al., 1999; Hugel and Schlichter, 2000; Patel et al., 2001).

View this table:
  • View inline
  • View popup
Table 3

Functional properties of recombinant heteromeric P2X receptors

VI. Native Receptors in Whole Tissues

A. Studies in Vitro

Rigorous studies in whole tissues have identified P2X receptors in smooth muscle preparations such as rat bladder and vas deferens and in neuronal preparations such as the isolated vagus nerve (Trezise et al., 1994a,b; Khakh et al., 1995b). These experiments thus extended earlier studies to pharmacologically define P2 receptors. However, all such studies have been confounded by marked ectonucleotidase activity, which interferes with both agonist and antagonist potency estimates (Humphrey et al., 1995). The same is true in brain slice electrophysiological studies, such as in the locus coeruleus, medial vestibular nucleus, and trigeminal mesencephalic nucleus, where good evidence for P2X receptors has been provided (Shen and North, 1993; Chessell et al., 1997b; Khakh et al., 1997). Even in single-cell recording systems, where such complications can be reduced, definitive receptor subtype identification remains difficult (Khakh et al., 1995a,b; Robertson et al., 1996). This results largely from the paucity of good selective drug tools. Thus, to better understand native P2X receptors in whole tissues we need more potent and selective agonists and antagonists to profile the functional properties of homomeric (Table 2), as well as heteromeric, P2X receptors (Torres et al., 1999; Table 3), to compare with those of P2X receptors in native systems (Table4). However, even with the limitations of the drug tools available it is possible to identify cell types that appear to contain particular P2X receptor subtypes, some of which appear to be homomeric and others, such as those in nodose and dorsal root ganglion cells, that appear to be heteromeric (see Table 4).

B. Studies in Vivo

Studies in vivo have indicated a number of potential physiological and pathophysiological roles for ATP in smooth muscle as well as neurons and inflammatory cells. Thus, in male transgenic mice lacking P2X1 receptors, contraction of the vas deferens in response to sympathetic nerve stimulation is substantially reduced and their fertility impaired by 90% (Mulryan et al., 2000). A growing body of evidence suggests that P2X receptors on nerve terminals both in the periphery and spinal dorsal horn are involved in sensory processing and nociception at sites throughout the body including the joints, viscera, and cardiovascular system (Burnstock, 1996, 2000; Pelleg and Hurt, 1996; Bland-Ward and Humphrey, 1997, 2000; McQueen et al., 1998;Kirkup et al., 1999; Tsuda et al., 1999). Studies in transgenic mice lacking the P2X3 have shown that formalin-induced pain behavior is reduced and that their ability to code the intensity of non-noxious heat stimulation is absent (Cockayne et al., 2000;Souslova et al., 2000). Interestingly these mice also exhibited a decreased urine voiding frequency and an increased bladder capacity associated with a normal intravesical pressure (Cockayne et al., 2000). This suggests a urinary bladder hyporeflexia, whereby the release of ATP on bladder distension no longer excites peripheral primary afferent nerve terminals (Cockayne et al., 2000). Recent studies in a P2X7-deficient mouse have confirmed earlier studies, which suggested that receptors may play an important role in initiating the processing and release of IL-1β from inflammatory cells (Ferrari et al., 1997; Grahames et al., 1999; Solle et al., 2001)

VII. Summary

In the last few years, spectacular advances have been made in our knowledge of P2X receptors and the biology of ATP itself, which appears to act as an important humoral regulator both physiologically and in disease. At the molecular level, we better understand the functional properties and identity of this whole new family of transmitter-gated cation channels. At the cellular level the use of antagonists and receptor knock-out studies are beginning to unravel the functional roles that P2X receptors and ATP play in vivo. Finally, the P2X Receptor Subcommittee of the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (NC-IUPHAR) recommends continued use of the present common nomenclature for P2X receptor subunits.

Acknowledgments

B. S. Khakh was supported by a Wellcome Trust (UK) International Prize Traveling Research Fellowship and Roche (Palo Alto, CA). We thank Dr. Terry Egan for comments on an earlier version of this paper.

Footnotes

  • ↵1 Address for correspondence: Baljit S. Khakh, Division of Neurobiology, MRC Laboratory of Molecular Biology, Hills Rd., Cambridge, CB2 2QH, UK. E-mail: bsk{at}mrc-lmb.cam.ac.uk or Patrick P. A. Humphrey, Glaxo Institute of Applied Pharmacology, University of Cambridge, Department of Pharmacology, Tennis Court Rd., Cambridge, CB2 1QJ UK. E-mail: ppah0562{at}glaxowellcome.co.uk

Abbreviations

SCG
superior cervical ganglion
CNS
central nervous system
PPADS
pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonic acid
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Alexander K,
    2. Niforatos W,
    3. Bianchi B,
    4. Burgard EC,
    5. Lynch KJ,
    6. Kowaluk EA,
    7. Jarvis MF,
    8. van Biesen T
    (1999) Allosteric modulation and accelerated resensitization of human P2X3 receptors by cibacron blue. J Pharmacol Exp Ther 291:1135–1142.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Arslan G,
    2. Filipeanu CM,
    3. Irenius E,
    4. Kull B,
    5. Clementi E,
    6. Allgaier C,
    7. Erlinge D,
    8. Fredholm BB
    (2000) P2Y receptors contribute to ATP-induced increases in intracellular calcium in differentiated but not undifferentiated PC12 cells. Neuropharmacology 39:482–396.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Benham CD
    (1989) ATP-activated channels gate calcium entry in single smooth muscle cells dissociated from rabbit ear artery. J Physiol (Lond) 419:689–701.
    OpenUrlPubMed
  4. ↵
    1. Benham CD,
    2. Bolton TB,
    3. Byrne NG,
    4. Large WA
    (1987) Action of externally applied adenosine triphosphate on single smooth muscle cells dispersed from rabbit ear artery. J Physiol (Lond) 387:473–488.
    OpenUrlPubMed
  5. ↵
    1. Benham CD,
    2. Tsien RW
    (1987) A novel receptor-operated Ca2+-permeable channel activated by ATP in smooth muscle. Nature (Lond) 328:275–278.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bland-Ward PA,
    2. Humphrey PPA
    (1997) Acute nociception mediated by hindpaw P2X receptor activation in the rat. Br J Pharmacol 122:365–371.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Bland-Ward PA,
    2. Humphrey PPA
    (2000) P2X receptors mediate ATP-induced primary nociceptive neurone activation. J Auton Nerv Syst 8:146–151.
    OpenUrl
  8. ↵
    1. Bo X,
    2. Schoepfer R,
    3. Burnstock G
    (2000) Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle. J Biol Chem 275:14401–14407.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Bo X,
    2. Sexton A,
    3. Xiang Z,
    4. Nori SL,
    5. Burnstock G
    (1998) Pharmacological and histochemical evidence for P2X receptors in human umbilical vessels. Eur J Pharmacol 353:59–65.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bo X,
    2. Simon J,
    3. Burnstock G,
    4. Barnard EA
    (1992) Solubilization and molecular size determination of the P2X purinoceptor from rat vas deferens. J Biol Chem 267:17581–17587.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Bo X,
    2. Zhang Y,
    3. Nassar M,
    4. Burnstock G,
    5. Schoepfer R
    (1995) A P2X purinoceptor cDNA conferring a novel pharmacological profile. FEBS Lett 375:129–133.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Boehm S
    (1999) ATP stimulates sympathetic transmitter release via presynaptic P2X purinoceptors. J Neurosci 19:737–746.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Boué-Grabot E,
    2. Archambault V,
    3. Séguéla P
    (2000) A protein kinase C site highly conserved in P2X subunits controls the desensitization kinetics of P2X2 ATP-gated channels J Biol Chem. 275:10190–10195.
  14. ↵
    1. Brake AJ,
    2. Wagenbach MJ,
    3. Julius D
    (1994) New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature (Lond) 371:519–523.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Brandle U,
    2. Spielmanns P,
    3. Osteroth R,
    4. Sim J,
    5. Surprenant A,
    6. Buell G,
    7. Ruppersberg JP,
    8. Plinkert PK,
    9. Zenner HP,
    10. Glowatski E
    (1997) Desensitization of the P2X2 receptor controlled by alternative splicing. FEBS Lett 404:294–298.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Buell G,
    2. Lewis C,
    3. Collo G,
    4. North RA,
    5. Surprenant A
    (1996a) An antagonist-insensitive P2X receptor expressed in epithelia and brain. EMBO J 15:55–62.
    OpenUrlPubMed
  17. ↵
    1. Buell G,
    2. Michel AD,
    3. Lewis C,
    4. Collo G,
    5. Humphrey PPA,
    6. Surprenant A
    (1996b) P2X1 receptor activation in HL60 cells. Blood 87:2659–2664.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Burgard EC,
    2. Niforatos W,
    3. van Biesen T,
    4. Lynch KJ,
    5. Touma E,
    6. Metzger RE,
    7. Kowaluk EA,
    8. Jarvis MF
    (1999) P2X receptor-mediated ionic currents in dorsal root ganglion neurons. J Neurophysiol 82:1590–1598.
    OpenUrlAbstract/FREE Full Text
    1. Burnashev N
    (1998) Calcium permeability of ligand-gated channels. Cell Calcium 24:325–332.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Burnstock G
    (1996) A unifying purinergic hypothesis for the initiation of pain. Lancet 347:1604–1605.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Burnstock G
    (2000) P2X receptors in sensory neurones. Br J Anaesth 84:476–488.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Burnstock G,
    2. Kennedy C
    (1985) Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16:433–440.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Chan CM,
    2. Unwin RJ,
    3. Bardini M,
    4. Oglesby IB,
    5. Ford AP,
    6. Townsend-Nicholson A,
    7. Burnstock G
    (1998) Localization of P2X1 purinoceptors by autoradiography and immunohistochemistry in rat kidneys. Am J Physiol 274:F799–F804.
    OpenUrl
  23. ↵
    1. Chen C,
    2. Parker MS,
    3. Barnes AP,
    4. Deininger P,
    5. Bobbin RP
    (2000) Functional expression of three P2X2 receptor splice variants from guinea pig cochlea. J Neurophysiol 83:1502–1509.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Chen CC,
    2. Akopian AN,
    3. Sivilotti L,
    4. Colquhoun D,
    5. Burnstock G,
    6. Wood JN
    (1995) A P2X purinoceptor expressed by a subset of sensory neurons. Nature (Lond) 377:428–431.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Chessell IP,
    2. Michel AD,
    3. Humphrey PPA
    (1997a) Properties of the pore-forming P2X7 purinoceptor in mouse NTW8 microglial cells. Br J Pharmacol 121:1429–1437.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Chessell IP,
    2. Michel AD,
    3. Humphrey PPA
    (1997b) Functional evidence for multiple purinoceptor subtypes in the rat medial vestibular nucleus. Neuroscience 77:783–791.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Chessell IP,
    2. Simon J,
    3. Hibell AD,
    4. Michel AD,
    5. Barnard EA,
    6. Humphrey PPA
    (1998a) Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett 439:26–30.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Chessell IP,
    2. Michel AD,
    3. Humphrey PPA
    (1998b) Effects of antagonists at the human recombinant P2X7 receptor. Br J Pharmacol 124:1314–1320.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Abbrachio MP,
    2. Williams M
    1. Chessell IP,
    2. Michel AD,
    3. Humphrey PPA
    (2001) in P2X Receptors in Purinergic and Pyrimidinergic Signalling I—Molecular, Nervous and Urogenitary System Function, eds Abbrachio MP, Williams M (Springer, Berlin), pp 47–63.
  30. ↵
    1. Clarke CE,
    2. Benham CD,
    3. Bridges A,
    4. George AR,
    5. Meadows HJ
    (2000) Mutation of histidine 286 of the human P2X4 purinoceptor removes extracellular pH sensitivity. J Physiol (Lond) 523:697–703.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Clifford EE,
    2. Parker K,
    3. Humphreys BD,
    4. Kertesy SB,
    5. Dubyak GR
    (1998) The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood 91:3172–3181.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Cockayne DA,
    2. Hamilton SG,
    3. Zhu QM,
    4. Dunn PM,
    5. Zhong Y,
    6. Novakovic S,
    7. Malmberg AB,
    8. Cain G,
    9. Berson A,
    10. Kassotakis L,
    11. Hedley L,
    12. Lachnit WG,
    13. Burnstock G,
    14. McMahon SB,
    15. Ford AP
    (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature (Lond) 407:1011–1015.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Cockcroft S,
    2. Gomperts BD
    (1979) ATP induces nucleotide permeability in rat mast cells. Nature (Lond) 279:541–542.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Collo G,
    2. Neidhart S,
    3. Kawashima E,
    4. Kosco-Vilbois M,
    5. North RA,
    6. Buell G
    (1997) Tissue distribution of the P2X7 receptor. Neuropharmacology 36:1277–1283.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Collo G,
    2. North RA,
    3. Kawashima E,
    4. Merlo-Pich E,
    5. Neidhart S,
    6. Surprenant A,
    7. Buell G
    (1996) Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. J Neurosci 16:2495–2507.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Colquhoun D
    (1998) Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 125:924–947.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Cook SP,
    2. Rodland KD,
    3. McCleskey EW
    (1998) A memory for extracellular Ca2+ by speeding recovery of P2X receptors from desensitization. J Neurosci 18:9238–9244.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Cook SP,
    2. Vulchanova L,
    3. Hargreaves KM,
    4. Elde R,
    5. McCleskey EW
    (1997) Distinct ATP receptors on pain-sensing and stretch-sensing neurons. Nature (Lond) 387:505–508.
    OpenUrlCrossRefPubMed
    1. Davies PA,
    2. Pistis M,
    3. Hanna MC,
    4. Peters JA,
    5. Lambert JJ,
    6. Hales TG,
    7. Kirkness EF
    (1999) The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature (Lond) 397:359–363.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Ding S,
    2. Sachs F
    (1999a) Ion permeation and block of P2X2 purinoceptors: Single channel recordings. J Membr Biol 172:215–223.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Ding S,
    2. Sachs F
    (1999b) Single channel properties of P2X2 purinoceptors. J Gen Physiol 113:695–720.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Ding S,
    2. Sachs F
    (2000) Inactivation of P2X2 purinoceptors by divalent cations. J Physiol (Lond) 522:199–214.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Dunn PM,
    2. Liu M,
    3. Zhong Y,
    4. King BF,
    5. Burnstock G
    (2000) Diinosine pentaphosphate: An antagonist which discriminates between recombinant P2X3 and P2X2/3 receptors and between two P2X receptors in rat sensory neurones. Br J Pharmacol 130:1378–1384.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Dunwiddie TV,
    2. Diao L,
    3. Proctor WR
    (1997) Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. J Neurosci 17:7673–7682.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Egan TM,
    2. Haines WR,
    3. Voigt MM
    (1998) A domain contributing to the ion channel of ATP-gated P2X2 receptors identified by the substituted cysteine accessibility method. J Neurosci 18:2350–2359.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Ennion S,
    2. Hagan S,
    3. Evans RJ
    (2000) The role of positively charged amino acids in ATP recognition by human P2X1 receptors. J Biol Chem 275:29361–29367.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Evans RJ,
    2. Kennedy C
    (1994) Characterisation of P2-purinoceptors in the smooth muscle of the rat tail artery: A comparison between contractile and electrophysiological responses. Br J Pharmacol 113:853–860.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Evans RJ,
    2. Lewis C,
    3. Virginio C,
    4. Lundstrom K,
    5. Buell G,
    6. Surprenant A,
    7. North RA
    (1996) Ionic permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X receptors) expressed in mammalian cells. J Physiol (Lond) 497:413–422.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Evans RJ,
    2. Surprenant A
    (1992) Vasoconstriction of guinea-pig submucosal arterioles following sympathetic nerve stimulation is mediated by the release of ATP. Br J Pharmacol 106:242–249.
    OpenUrlCrossRefPubMed
  49. ↵
    1. Ferrari D,
    2. Chiozzi P,
    3. Falzoni S,
    4. Hanau S,
    5. Di Virgilio F
    (1997) Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med 185:579–582.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Fox JA
    (1987) Ion channel subconductance states. J Membr Biol 97:1–8.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Fredholm BB,
    2. Abbracchio MP,
    3. Burnstock G,
    4. Daly JW,
    5. Harden TK,
    6. Jacobson KA,
    7. Leff P,
    8. Williams M
    (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143–156.
    OpenUrlPubMed
  52. ↵
    1. Friel DD
    (1988) An ATP-sensitive conductance in single smooth muscle cells from the rat vas deferens. J Physiol (Lond) 401:361–380.
    OpenUrlPubMed
  53. ↵
    1. Friel DD,
    2. Bean BP
    (1988) Two ATP-activated conductances in bullfrog atrial cells. J Gen Physiol 91:1–27.
    OpenUrlAbstract/FREE Full Text
    1. Fucile S,
    2. Palma E,
    3. Mileo AM,
    4. Miledi R,
    5. Eusebi F
    (2000) Human neuronal threonine-for-leucine-248 alpha 7 mutant nicotinic acetylcholine receptors are highly Ca2+ permeable. Proc Natl Acad Sci USA 97:3643–3648.
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. Garcia-Guzman M,
    2. Soto F,
    3. Gomez-Hernandez JM,
    4. Lund PE,
    5. Stuhmer W
    (1997) Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. Mol Pharmacol 51:109–118.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Garcia-Guzman M,
    2. Soto F,
    3. Laube B,
    4. Stuhmer W
    (1996) Molecular cloning and functional expression of a novel rat heart P2X purinoceptor. FEBS Lett 388:123–127.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Garcia-Lecea M,
    2. Delicado EG,
    3. Miras-Portugal MT,
    4. Castro E
    (1999) P2X2 characteristics of the ATP receptor coupled to [Ca2+]i increases in cultured Purkinje neurons from neonatal rat cerebellum. Neuropharmacology 38:699–706.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Gibson F
    (1982) The Leeuwenhoek Lecture, 1981. The biochemical and genetic approach to the study of bioenergetics with the use of Escherichia coli: Progress and prospects. Proc R Soc Lond Ser B Biol Sci 215:1–18.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Grahames CB,
    2. Michel AD,
    3. Chessell IP,
    4. Humphrey PPA
    (1999) Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br J Pharmacol 127:1915–1921.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Grosman C,
    2. Zhou M,
    3. Auerbach A
    (2000) Mapping the conformational wave of acetylcholine receptor channel gating. Nature (Lond) 403:773–779.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Grubb B,
    2. Evans R
    (1999) Characterization of cultured dorsal root ganglion neuron P2X receptors. Eur J Neurosci 11:149–154.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Haines WR,
    2. Torres GE,
    3. Voigt MM,
    4. Egan TM
    (1999) Properties of the novel ATP-gated ionotropic receptor composed of the P2X1 and P2X5 isoforms. Mol Pharmacol 56:720–727.
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. Hargreaves AC,
    2. Pollard CE
    (2000) Characterisation of P2X7 receptors in human cultured dendritic cells (Abstract). J Invest Dermatol 114:069.
    OpenUrl
  63. ↵
    1. Hibell AD,
    2. Kidd EJ,
    3. Chessell IP,
    4. Humphrey PPA,
    5. Michel AD
    (2000) Apparent species differences in the kinetic properties of P2X7 receptors. Br J Pharmacol 130:167–173.
    OpenUrlCrossRefPubMed
  64. ↵
    1. Hinkle PE,
    2. McCarty RE
    (1978) How cells make ATP. Sci Am 238:104–123.
    OpenUrlPubMed
  65. ↵
    1. Honore E,
    2. Martin C,
    3. Mironneau C,
    4. Mironneau J
    (1989) An ATP-sensitive conductance in cultured smooth muscle cells from pregnant rat myometrium. Am J Physiol 257:C297–C305.
    OpenUrl
  66. ↵
    1. Housley GD,
    2. Kanjhan R,
    3. Raybould NP,
    4. Greenwood D,
    5. Salih SG,
    6. Jarlebark L,
    7. Burton LD,
    8. Setz VC,
    9. Cannell MB,
    10. Soeller C,
    11. Christie DL,
    12. Usami S,
    13. Matsubara A,
    14. Yoshie H,
    15. Ryan AF,
    16. Thorne PR
    (1999) Expression of the P2X2 receptor subunit of the ATP-gated ion channel in the cochlea: Implications for sound transduction and auditory neurotransmission. J Neurosci 19:8377–8388.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Hugel S,
    2. Schlichter R
    (2000) Presynaptic P2X receptors facilitate inhibitory GABAergic transmission between cultured rat spinal cord dorsal horn neurons J Neurosci 20:2121–2130.
  68. ↵
    1. Humphrey PPA,
    2. Buell G,
    3. Kennedy I,
    4. Khakh BS,
    5. Michel AD,
    6. Surprenant A,
    7. Trezise DJ
    (1995) New insights on P2X purinoceptors. Naunyn-Schmiedebergs Arch Pharmacol 352:585–596.
    OpenUrlPubMed
  69. ↵
    1. Humphrey PPA,
    2. Khakh BS,
    3. Kennedy C,
    4. King BF,
    5. Burnstock G
    (1998) P2X Receptors. The IUPHAR Compendium of Receptor Characterization and Classification (International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification) (IUPHAR Media, London), pp 195–208.
  70. ↵
    1. Humphreys BD,
    2. Virginio C,
    3. Surprenant A,
    4. Rice J,
    5. Dubyak GR
    (1998) Isoquinolines as antagonists of the P2X7 nucleotide receptor: High selectivity for the human versus rat receptor homologues. Mol Pharmacol 54:22–32.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Inoue R,
    2. Brading AF
    (1990) The properties of the ATP-induced depolarization and current in single cells isolated from the guinea-pig urinary bladder. Br J Pharmacol 100:619–625.
    OpenUrlPubMed
  72. ↵
    1. Jahr CE,
    2. Jessell TM
    (1983) ATP excites a subpopulation of rat dorsal horn neurones. Nature (Lond) 304:730–733.
    OpenUrlCrossRefPubMed
  73. ↵
    1. Jiang L-H,
    2. Rassendren F,
    3. Surprenant A,
    4. North RA
    (2000) Identification of amino acid residues contributing to the ATP binding site of a P2X receptor. J Biol Chem 275:34190–34196.
    OpenUrlAbstract/FREE Full Text
  74. ↵
    1. Jones CA,
    2. Chessell IP,
    3. Simon J,
    4. Barnard EA,
    5. Miller KJ,
    6. Michel AD,
    7. Humphrey PPA
    (2000) Functional characterization of the P2X4 receptor orthologues. Br J Pharmacol 129:388–394.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Kennedy C,
    2. Leff P
    (1995) How should P2X purinoceptors be classified pharmacologically. Trends Pharmacol Sci 16:168–174.
    OpenUrlCrossRefPubMed
  76. ↵
    1. Khakh B,
    2. Bao X,
    3. Labarca C,
    4. Lester H
    (1999a) Neuronal P2X receptor-transmitter-gated cation channels change their ion selectivity in seconds. Nat Neurosci 2:322–330.
    OpenUrlCrossRefPubMed
  77. ↵
    1. Khakh BS,
    2. Humphrey PPA,
    3. Henderson G
    (1997) ATP-gated cation channels (P2X purinoceptors) in trigeminal mesencephalic nucleus neurons of the rat. J Physiol (Lond) 498:709–715.
    OpenUrlPubMed
  78. ↵
    1. Khakh BS,
    2. Humphrey PPA,
    3. Surprenant A
    (1995a) Electrophysiological properties of P2X-purinoceptors in rat superior cervical, nodose and guinea-pig coeliac neurones. J Physiol (Lond) 484:385–395.
    OpenUrlPubMed
  79. ↵
    1. Khakh BS,
    2. Kennedy C,
    3. King BF,
    4. Barnard EA,
    5. Burnstock G,
    6. North RA,
    7. Voigt M,
    8. Humphrey PPA
    (2000a) Nucleotide Receptors, P2X Receptors. The IUPHAR Compendium of Receptor Characterization and Classification. (IUPHAR Media, London).
  80. ↵
    1. Khakh BS,
    2. Lester HA
    (1999) Dynamic selectivity filters in ion channels. Neuron 23:653–658.
    OpenUrlCrossRefPubMed
  81. ↵
    1. Khakh BS,
    2. Michel A,
    3. Humphrey PPA
    (1994) Estimates of antagonist affinities at P2X purinoceptors in rat vas deferens. Eur J Pharmacol 263:301–309.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Khakh BS,
    2. Proctor WR,
    3. Dunwiddie TV,
    4. Labarca C,
    5. Lester HA
    (1999b) Allosteric control of gating and kinetics at P2X4 receptor channels. J Neurosci 19:7289–7299.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Khakh BS,
    2. Surprenant A,
    3. Humphrey PPA
    (1995b) A study on P2X purinoceptors mediating the electrophysiological and contractile effects of purine nucleotides in rat vas deferens. Br J Pharmacol 115:177–185.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Khakh BS,
    2. Zhou X,
    3. Sydes J,
    4. Galligan JJ,
    5. Lester HA
    (2000b) State-dependent cross-inhibition between transmitter-gated cation channels. Nature (Lond) 406:405–410.
    OpenUrlCrossRefPubMed
  85. ↵
    1. Kidd EJ,
    2. Grahames CB,
    3. Simon J,
    4. Michel AD,
    5. Barnard EA,
    6. Humphrey PPA
    (1995) Localization of P2X purinoceptor transcripts in the rat nervous system. Mol Pharmacol 48:569–573.
    OpenUrlAbstract
  86. ↵
    1. Kim M,
    2. Yoo OJ,
    3. Choe S
    (1997) Molecular assembly of the extracellular domain of P2X2, an ATP-gated ion channel. Biochem Biophys Res Commun 240:618–622.
    OpenUrlCrossRefPubMed
  87. ↵
    1. King BF,
    2. Chen CC,
    3. Akopian AN,
    4. Burnstock G,
    5. Wood JN
    (1996) A role for calcineurin in the desensitization of the P2X3 receptor. Neuroreport 8:1099–1102.
    OpenUrl
  88. ↵
    1. King BF,
    2. Liu M,
    3. Pintor J,
    4. Gualix J,
    5. Miras-Portugal MT,
    6. Burnstock G
    (1999) Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. Br J Pharmacol 128:981–988.
    OpenUrlCrossRefPubMed
  89. ↵
    1. King BF,
    2. Townsend-Nicholson A,
    3. Wildman SS,
    4. Thomas T,
    5. Spyer KM,
    6. Burnstock G
    (2000) Coexpression of rat P2X2 and P2X6 subunits in Xenopus oocytes. J Neurosci 20:4871–4877.
    OpenUrlAbstract/FREE Full Text
  90. ↵
    1. Kirkup AJ,
    2. Booth CE,
    3. Chessell IP,
    4. Humphrey PPA,
    5. Grundy D
    (1999) Excitatory effect of P2X receptor activation on mesenteric afferent nerves in the anaesthetised rat. J Physiol (Lond) 520:551–563.
    OpenUrlCrossRefPubMed
  91. ↵
    1. Koshimizu T,
    2. Koshimizu M,
    3. Stojilkovic SS
    (1999) Contributions of the C-terminal domain to the control of P2X receptor desensitization. J Biol Chem 274:37651–37657.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Koshimizu T-A,
    2. Tomi M,
    3. Koshimizu M,
    4. Stojilkovic SS
    (1998) Identification of amino acid residues contributing to desensitization of the P2X2 receptor channel. J Biol Chem 273:12853–12857.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Krause RM,
    2. Buisson B,
    3. Bertrand S,
    4. Corringer PJ,
    5. Galzi JL,
    6. Changeux JP,
    7. Bertrand D
    (1998) Ivermectin: A positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53:283–294.
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Krishtal OA,
    2. Marchenko SM,
    3. Obukhov AG
    (1988a) Cationic channels activated by extracellular ATP in rat sensory neurons. Neuroscience 27:995–1000.
    OpenUrlCrossRefPubMed
  95. ↵
    1. Krishtal OA,
    2. Marchenko SM,
    3. Obukhov AG,
    4. Volkova TM
    (1988b) Receptors for ATP in rat sensory neurones: The structure-function relationship for ligands. Br J Pharmacol 95:1057–1062.
    OpenUrlPubMed
  96. ↵
    1. Krishtal OA,
    2. Marchenko SM,
    3. Pidoplichko VI
    (1983) Receptor for ATP in the membrane of mammalian sensory neurones. Neurosci Lett 31:41–45.
    OpenUrl
  97. ↵
    1. Krusek J,
    2. Zemkova H
    (1994) Effect of ivermectin on gamma-aminobutyric acid-induced chloride currents in mouse hippocampal embryonic neurones. Eur J Pharmacol 259:121–128.
    OpenUrlCrossRefPubMed
  98. ↵
    1. Le KT,
    2. Babinski K,
    3. Séguéla P
    (1998a) Central P2X4 and P2X6 channel subunits coassemble into a novel heteromeric ATP receptor. J Neurosci 18:7152–7159.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Le KT,
    2. Boue-Grabot E,
    3. Archambault V,
    4. Séguéla P
    (1999) Functional and biochemical evidence for heteromeric ATP-gated channels composed of P2X1 and P2X5 subunits. J Biol Chem 274:15415–15419.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Le KT,
    2. Paquet M,
    3. Nouel D,
    4. Babinski K,
    5. Séguéla P
    (1997) Primary structure and expression of a naturally truncated human P2X ATP receptor subunit from brain and immune system. FEBS Lett 418:195–199.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Le KT,
    2. Villeneuve P,
    3. Ramjaun AR,
    4. McPherson PS,
    5. Beaudet A,
    6. Séguéla P
    (1998b) Sensory presynaptic and widespread somatodendritic immunolocalization of central ionotropic P2X ATP receptors. Neuroscience 83:177–190.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Lewis C,
    2. Neidhart S,
    3. Holy C,
    4. North RA,
    5. Buell G,
    6. Surprenant A
    (1995) Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons. Nature (Lond) 377:432–435.
    OpenUrlCrossRefPubMed
  103. ↵
    1. Lewis CJ,
    2. Evans RJ
    (2000) Comparison of P2X receptors in rat mesenteric, basilar and septal (coronary) arteries. J Auton Nerv Syst 81:69–74.
    OpenUrlCrossRefPubMed
  104. ↵
    1. Lewis CJ,
    2. Surprenant A,
    3. Evans RJ
    (1998) 2′,3′-O-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate (TNP-ATP)–a nanomolar affinity antagonist at rat mesenteric artery P2X receptor ion channels. Br J Pharmacol 124:1463–1466.
    OpenUrlCrossRefPubMed
  105. ↵
    1. Li C
    (2000) Novel mechanism of inhibition by the P2 receptor antagonist PPADS of ATP-activated current in dorsal root ganglion neurons. J Neurophysiol 83:2533–2541.
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Liu M,
    2. Dunn PM,
    3. King B,
    4. Burnstock G
    (1999) Rat chromaffin cells lack P2X receptors while those of the guinea-pig express a P2X receptor with novel pharmacology. Br J Pharmacol 128:61–68.
    OpenUrlCrossRefPubMed
  107. ↵
    1. Loesch A,
    2. Burnstock G
    (1998) Electron-immunocytochemical localization of P2X1 receptors in the rat cerebellum. Cell Tissue Res 294:253–260.
    OpenUrlCrossRefPubMed
  108. ↵
    1. McCleskey EW,
    2. Gold MS
    (1999) Ion channels of nociception. Annu Rev Physiol 61:835–856.
    OpenUrlCrossRefPubMed
  109. ↵
    1. McLaren GJ,
    2. Burke KS,
    3. Buchanan KJ,
    4. Sneddon P,
    5. Kennedy C
    (1998) Evidence that ATP acts at two sites to evoke contraction in the rat isolated tail artery. Br J Pharmacol 124:5–12.
    OpenUrlCrossRefPubMed
  110. ↵
    1. McQueen DS,
    2. Bond SM,
    3. Moores C,
    4. Chessell IP,
    5. Humphrey PPA,
    6. Dowd E
    (1998) Activation of P2X receptors for adenosine triphosphate evokes cardiorespiratory reflexes in anaesthetized rats. J Physiol (Lond) 507:843–855.
    OpenUrlCrossRefPubMed
  111. ↵
    1. Michel AD,
    2. Grahames CB,
    3. Humphrey PPA
    (1996a) Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx. Naunyn-Schmiedebergs Arch Pharmacol 354:562–571.
    OpenUrlPubMed
  112. ↵
    1. Michel AD,
    2. Lundstrom K,
    3. Buell GN,
    4. Surprenant A,
    5. Valera S,
    6. Humphrey PPA
    (1996b) A comparison of the binding characteristics of recombinant P2X1 and P2X2purinoceptors. Br J Pharmacol 118:1806–1812.
    OpenUrlPubMed
  113. ↵
    1. Michel AD,
    2. Miller KJ,
    3. Lundstrom K,
    4. Buell GN,
    5. Humphrey PPA
    (1997) Radiolabeling of the rat P2X4 purinoceptor: Evidence for allosteric interactions of purinoceptor antagonists and monovalent cations with P2X purinoceptors. Mol Pharmacol 51:524–532.
    OpenUrlAbstract/FREE Full Text
  114. ↵
    1. Miller KJ,
    2. Michel AD,
    3. Chessell IP,
    4. Humphrey PPA
    (1998) Cibacron blue allosterically modulates the rat P2X4 receptor. Neuropharmacology 37:1579–1586.
    OpenUrlCrossRefPubMed
  115. ↵
    1. Mulryan K,
    2. Gitterman DP,
    3. Lewis CJ,
    4. Vial C,
    5. Leckie BJ,
    6. Cobb AL,
    7. Brown JE,
    8. Conley EC,
    9. Buell G,
    10. Pritchard CA,
    11. Evans RJ
    (2000) Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature (Lond) 403:86–89.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Nabekura J,
    2. Ueno S,
    3. Ogawa T,
    4. Akaike N
    (1995) Colocalization of ATP and nicotinic ACh receptors in the identified vagal preganglionic neurone of rat. J Physiol (Lond) 489:519–527.
    OpenUrlPubMed
  117. ↵
    1. Nakazawa K,
    2. Hess P
    (1993) Block by calcium of ATP-activated channels in pheochromocytoma cells. J Gen Physiol 101:377–392.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Nakazawa K,
    2. Inoue K,
    3. Ito K,
    4. Koizumi S,
    5. Inoue K
    (1995) Inhibition by suramin and reactive blue 2 of GABA and glutamate receptor channels in rat hippocampal neurons. Naunyn-Schmiedebergs Arch Pharmacol 351:202–208.
    OpenUrlPubMed
  119. ↵
    1. Nakazawa K,
    2. Matsuki N
    (1987) Adenosine triphosphate-activated inward current in isolated smooth muscle cells from rat vas deferens. Pflugers Arch 409:644–666.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Newbolt A,
    2. Stoop R,
    3. Virginio C,
    4. Surprenant A,
    5. North RA,
    6. Buell G,
    7. Rassendren F
    (1998) Membrane topology of an ATP-gated ion channel (P2X receptor). J Biol Chem 273:15177–15182.
    OpenUrlAbstract/FREE Full Text
  121. ↵
    1. Nicke A,
    2. Baumert HG,
    3. Rettinger J,
    4. Eichele A,
    5. Lambrecht G,
    6. Mutschler E,
    7. Schmalzing G
    (1998) P2X1 and P2X3 receptors form stable trimers: A novel structural motif of ligand-gated ion channels. EMBO J 17:3016–3028.
    OpenUrlAbstract
  122. ↵
    1. Nori S,
    2. Fumagalli L,
    3. Bo X,
    4. Bogdanov Y,
    5. Burnstock G
    (1998) Coexpression of mRNAs for P2X1, P2X2 and P2X4 receptors in rat vascular smooth muscle: An in situ hybridization and RT-PCR study. J Vasc Res 35:179–185.
    OpenUrlCrossRefPubMed
  123. ↵
    1. North RA,
    2. Surprenant A
    (2000) Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40:563–580.
    OpenUrlCrossRefPubMed
  124. ↵
    1. Nuttle LC,
    2. Dubyak GR
    (1994) Differential activation of cation channels and non-selective pores by macrophage P2z purinergic receptors expressed in Xenopus oocytes. J Biol Chem 269:13988–13996.
    OpenUrlAbstract/FREE Full Text
  125. ↵
    1. Patel M,
    2. Khakh BS,
    3. Henderson G
    (2001) Properties of native P2X receptors in rat trigeminal mesencephalic nucleus neurones: Lack of correlation with known heterologously expressed P2X receptors. Neuropharmacology 40:96–105.
    OpenUrlCrossRefPubMed
  126. ↵
    1. Pelleg A,
    2. Hurt CM
    (1996) Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals. J Physiol (Lond) 490:265–275.
    OpenUrlPubMed
  127. ↵
    1. Proctor W,
    2. Dunwiddie T
    (1998) Responses to ATP application on interneurons in hippocampal brain slices show prolonged desensitization. Soc Neurosci Abstr 630:8.
    OpenUrl
  128. ↵
    1. Proctor W,
    2. Dunwiddie TV,
    3. Lester HA,
    4. Khakh BS
    (1999) Hippocampal CA1 pyramidal neurons have functional purinergic receptors with pharmacological properties unlike those of recombinant P2X4 channels. Soc Neurosci Abstr 70:10.
    OpenUrl
  129. ↵
    1. Radford KM,
    2. Virginio C,
    3. Surprenant A,
    4. North RA,
    5. Kawashima E
    (1997) Baculovirus expression provides direct evidence for heteromeric assembly of P2X2 and P2X3 receptors. J Neurosci 17:6529–6533.
    OpenUrlAbstract/FREE Full Text
  130. ↵
    1. Rae MG,
    2. Rowan EG,
    3. Kennedy C
    (1998) Pharmacological properties of P2X3-receptors present in neurones of the rat dorsal root ganglia. Br J Pharmacol 124:176–180.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Rassendren F,
    2. Buell G,
    3. Newbolt A,
    4. North RA,
    5. Surprenant A
    (1997a) Identification of amino acid residues contributing to the pore of a P2X receptor. EMBO J 16:3446–3454.
    OpenUrlAbstract
  132. ↵
    1. Rassendren F,
    2. Buell GN,
    3. Virginio C,
    4. Collo G,
    5. North RA,
    6. Surprenant A
    (1997b) The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272:5482–5786.
    OpenUrlAbstract/FREE Full Text
  133. ↵
    1. Rettinger J,
    2. Aschrafi A,
    3. Schmalzing G
    (2000) Roles of individual N-glycans for ATP potency and expression of the rat P2X1 receptor. J Biol Chem 275:33542–33547.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Robertson SJ,
    2. Rae MG,
    3. Rowan EG,
    4. Kennedy C
    (1996) Characterisation of a P2X-purinoceptor in cultured neurones of the rat dorsal root ganglia. Br J Pharmacol 118:951–956.
    OpenUrlPubMed
  135. ↵
    1. Rogers M,
    2. Colquhoun LM,
    3. Patrick JW,
    4. Dani JA
    (1997) Calcium flux through predominantly independent purinergic ATP and nicotinic acetylcholine receptors. J Neurophysiol 77:1407–1417.
    OpenUrlAbstract/FREE Full Text
  136. ↵
    1. Rogers M,
    2. Dani JA
    (1995) Comparison of quantitative calcium flux through NMDA, ATP, and ACh receptor channels. Biophys J 68:501–506.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Salih SG,
    2. Housley GD,
    3. Raybould NP,
    4. Thorne PR
    (1999) ATP-gated ion channel expression in primary auditory neurones. Neuroreport 10:2579–2586.
    OpenUrlPubMed
  138. ↵
    1. Scase TJ,
    2. Heath MF,
    3. Allen JM,
    4. Sage SO,
    5. Evans RJ
    (1998) Identification of a P2X1 purinoceptor expressed on human platelets. Biochem Biophys Res Commun 242:525–528.
    OpenUrlCrossRefPubMed
  139. ↵
    1. Séguéla P,
    2. Haghighi A,
    3. Soghomonian JJ,
    4. Cooper E
    (1996) A novel neuronal P2X ATP receptor ion channel with widespread distribution in the brain. J Neurosci 16:448–455.
    OpenUrlAbstract/FREE Full Text
    1. Séguéla P,
    2. Wadiche J,
    3. Dineley-Miller K,
    4. Dani JA,
    5. Patrick JW
    (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: A nicotinic cation channel highly permeable to calcium. J Neurosci 13:596–604.
    OpenUrlAbstract
  140. ↵
    1. Shen KZ,
    2. North RA
    (1993) Excitation of rat locus coeruleus neurons by adenosine 5′-triphosphate: Ionic mechanism and receptor characterization. J Neurosci 13:894–899.
    OpenUrlAbstract
  141. ↵
    1. Simon J,
    2. Kidd EJ,
    3. Smith FM,
    4. Chessell IP,
    5. Murrell-Lagnado R,
    6. Humphrey PPA,
    7. Barnard EA
    (1997) Localization and functional expression of splice variants of the P2X2 receptor. Mol Pharmacol 52:237–248.
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Smith FM,
    2. Humphrey PPA,
    3. Murrell-Lagnado RD
    (1999) Identification of amino acids within the P2X2 receptor C-terminus that regulate desensitization. J Physiol (Lond) 520:91–99.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Solle M,
    2. Labasi J,
    3. Perregaux DG,
    4. Stam E,
    5. Petrushova N,
    6. Koller BH,
    7. Griffiths RJ,
    8. Gabel CA
    (2001) Altered cytokine production in mice lacking P2X7 receptors. J Biol Chem 276:125–132.
    OpenUrlAbstract/FREE Full Text
  144. ↵
    1. Soto F,
    2. Garcia-Guzman M,
    3. Gomez-Hernandez JM,
    4. Hollmann M,
    5. Karschin C,
    6. Stuhmer W
    (1996a) P2X4: An ATP-activated ionotropic receptor cloned from rat brain. Proc Natl Acad Sci USA 93:3684–3688.
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Soto F,
    2. Garcia-Guzman M,
    3. Karschin C,
    4. Stuhmer W
    (1996b) Cloning and tissue distribution of a novel P2X receptor from rat brain. Biochem Biophys Res Commun 223:456–460.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Souslova V,
    2. Cesare P,
    3. Ding Y,
    4. Akopian AN,
    5. Stanfa L,
    6. Suzuki R,
    7. Carpenter K,
    8. Dickenson A,
    9. Boyce S,
    10. Hill R,
    11. Nebenuis-Oosthuizen D,
    12. Smith AJ,
    13. Kidd EJ,
    14. Wood JN
    (2000) Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature (Lond) 407:1015–1017.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Stoop R,
    2. Surprenant A,
    3. North RA
    (1997) Different sensitivities to pH of ATP-induced currents at four cloned P2X receptors. J Neurophysiol 78:1837–1840.
    OpenUrlAbstract/FREE Full Text
  148. ↵
    1. Stoop R,
    2. Thomas S,
    3. Rassendren F,
    4. Kawashima E,
    5. Buell G,
    6. Surprenant A,
    7. North R
    (1999) Contribution of individual subunits to the multimeric P2X2 receptor: Estimates based on methanethiosulfonate block at T336C. Mol Pharmacol 56:973–981.
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Surprenant A,
    2. Buell G,
    3. North RA
    (1995) P2X receptors bring new structure to ligand-gated ion channels. Trends Neurosci 18:224–229.
    OpenUrlCrossRefPubMed
  150. ↵
    1. Surprenant A,
    2. Rassendren F,
    3. Kawashima E,
    4. North RA,
    5. Buell G
    (1996) The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (Wash DC) 272:735–738.
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Surprenant A,
    2. Schneider DA,
    3. Wilson HL,
    4. Galligan JJ,
    5. North RA
    (2000) Functional properties of heteromeric P2X1/5 receptors expressed in HEK cells and excitatory junction potentials in guinea-pig submucosal arterioles. J Auton Nerv Syst 81:249–263.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Suzuki H
    (1985) Electrical responses of smooth muscle cells of the rabbit ear artery to adenosine triphosphate. J Physiol (Lond) 359:401–415.
    OpenUrlPubMed
  153. ↵
    1. Taschenberger H,
    2. Juttner R,
    3. Grantyn R
    (1999) Ca2+-permeable P2X receptor channels in cultured rat retinal ganglion cells. J Neurosci 19:3353–3366.
    OpenUrlAbstract/FREE Full Text
  154. ↵
    1. Thomas S,
    2. Virginio C,
    3. North RA,
    4. Surprenant A
    (1998) The antagonist trinitrophenyl-ATP reveals co-existence of distinct P2X receptor channels in rat nodose neurones. J Physiol (Lond) 509:411–417.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Torres G,
    2. Egan T,
    3. Voigt M
    (1999) Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. J Biol Chem 274:6653–6659.
    OpenUrlAbstract/FREE Full Text
  156. ↵
    1. Torres GE,
    2. Egan TM,
    3. Voigt MM
    (1998a) N-Linked glycosylation is essential for the functional expression of the recombinant P2X2 receptor. Biochemistry 37:4845–4851.
    OpenUrl
  157. ↵
    1. Torres GE,
    2. Haines WR,
    3. Egan TM,
    4. Voigt MM
    (1998b) Co-expression of P2X1 and P2X5 receptor subunits reveals a novel ATP-gated ion channel. Mol Pharmacol 54:989–993.
    OpenUrlAbstract/FREE Full Text
  158. ↵
    1. Townsend-Nicholson A,
    2. King BF,
    3. Wildman SS,
    4. Burnstock G
    (1999) Molecular cloning, functional characterization and possible cooperativity between the murine P2X4 and P2X4a receptors. Brain Res Mol Brain Res 64:246–254.
    OpenUrlPubMed
  159. ↵
    1. Trezise DJ,
    2. Kennedy I,
    3. Humphrey PPA
    (1994a) Characterization of purinoceptors mediating depolarization of rat isolated vagus nerve. Br J Pharmacol 110:1055–1060.
    OpenUrl
  160. ↵
    1. Trezise DJ,
    2. Kennedy I,
    3. Humphrey PPA
    (1994b) The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5′-triphosphate. Br J Pharmacol 112:282–288.
    OpenUrlPubMed
  161. ↵
    1. Trezise DJ,
    2. Michel AD,
    3. Grahames CB,
    4. Khakh BS,
    5. Surprenant A,
    6. Humphrey PPA
    (1995) The selective P2X purinoceptor agonist, beta, gamma-methylene-L-adenosine 5′-triphosphate, discriminates between smooth muscle and neuronal P2X purinoceptors. Naunyn-Schmiedebergs Arch Pharmacol 351:603–609.
    OpenUrlPubMed
  162. ↵
    1. Troadec JD,
    2. Thirion S,
    3. Nicaise G,
    4. Lemos JR,
    5. Dayanithi G
    (1998) ATP-evoked increases in [Ca2+]i and peptide release from rat isolated neurohypophysial terminals via a P2X2 purinoceptor. J Physiol (Lond) 15:89–103.
    OpenUrl
  163. ↵
    1. Tsuda M,
    2. Ueno S,
    3. Inoue K
    (1999) Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice. Br J Pharmacol 128:1497–1504.
    OpenUrlCrossRefPubMed
  164. ↵
    1. Ueno S,
    2. Tsuda M,
    3. Iwanaga T,
    4. Inoue K
    (1999) Cell type-specific ATP-activated responses in rat dorsal root ganglion neurons. Br J Pharmacol 126:429–436.
    OpenUrlCrossRefPubMed
  165. ↵
    1. Valera S,
    2. Hussy N,
    3. Evans RJ,
    4. Adami N,
    5. North RA,
    6. Surprenant A,
    7. Buell G
    (1994) A new class of ligand-gated ion channel defined by P2X receptor for extracellular ATP. Nature (Lond) 371:516–519.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Virginio C,
    2. Church D,
    3. North RA,
    4. Surprenant A
    (1997) Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor. Neuropharmacology 36:1285–1294.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Virginio C,
    2. MacKenzie A,
    3. North RA,
    4. Surprenant A
    (1999a) Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol (Lond) 519:335–346.
    OpenUrlCrossRefPubMed
  168. ↵
    1. Virginio C,
    2. MacKenzie A,
    3. Rassendren FA,
    4. North RA,
    5. Surprenant A
    (1999b) Pore dilation of neuronal P2X receptor channels. Nat Neurosci 2:315–321.
    OpenUrlCrossRefPubMed
  169. ↵
    1. Virginio C,
    2. North RA,
    3. Surprenant A
    (1998a) Calcium permeability and block at homomeric and heteromeric P2X2 and P2X3 receptors, and P2X receptors in rat nodose neurones. J Physiol (Lond) 510:27–35.
    OpenUrlCrossRefPubMed
  170. ↵
    1. Virginio C,
    2. Robertson G,
    3. Surprenant A,
    4. North RA
    (1998b) Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol 53:969–973.
    OpenUrlAbstract/FREE Full Text
  171. ↵
    1. Vulchanova L,
    2. Arvidsson U,
    3. Riedl M,
    4. Wang J,
    5. Buell G,
    6. Surprenant A,
    7. North RA,
    8. Elde R
    (1996) Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc Natl Acad Sci USA 93:8063–8067.
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Vulchanova L,
    2. Riedl MS,
    3. Shuster SJ,
    4. Buell G,
    5. Surprenant A,
    6. North RA,
    7. Elde R
    (1997) Immunohistochemical study of the P2X2 and P2X3 receptor subunits in rat and monkey sensory neurons and their central terminals. Neuropharmacology 36:1229–1242.
    OpenUrlCrossRefPubMed
  173. ↵
    1. Werner P,
    2. Seward EP,
    3. Buell GN,
    4. North RA
    (1996) Domains of P2X receptors involved in desensitization. Proc Natl Acad Sci USA 24:15485–15490.
    OpenUrl
  174. ↵
    1. Wildman SS,
    2. King BF,
    3. Burnstock G
    (1997) Potentiation of ATP-responses at a recombinant P2X2 receptor by neurotransmitters and related substances. Br J Pharmacol 120:221–224.
    OpenUrlCrossRefPubMed
  175. ↵
    1. Wildman SS,
    2. King BF,
    3. Burnstock G
    (1998) Zn2+ modulation of ATP-responses at recombinant P2X2 receptors and its dependence on extracellular pH. Br J Pharmacol 123:1214–1220.
    OpenUrlCrossRefPubMed
  176. ↵
    1. Wildman SS,
    2. King BF,
    3. Burnstock G
    (1999) Modulatory activity of extracellular H+ and Zn2+ on ATP-responses at rP2X1 and rP2X3 receptors. Br J Pharmacol 128:486–492.
    OpenUrlCrossRefPubMed
  177. ↵
    1. Xiong K,
    2. Peoples RW,
    3. Montgomery JP,
    4. Chiang Y,
    5. Stewart RR,
    6. Weight FF,
    7. Li C
    (1999) Differential modulation by copper and zinc of P2X2 and P2X4 receptor function. J Neurophysiol 81:2088–2094.
    OpenUrlAbstract/FREE Full Text
  178. ↵
    1. Zhong Y,
    2. Dunn PM,
    3. Burnstock G
    (2000a) Guinea-pig sympathetic neurons express varying proportions of two distinct P2X receptors. J Physiol (Lond) 523:391–402.
    OpenUrlCrossRefPubMed
  179. ↵
    1. Zhong Y,
    2. Dunn PM,
    3. Burnstock G
    (2000b) Pharmacological comparison of P2X receptors on rat coeliac, mouse coeliac and mouse pelvic ganglion neurons. Neuropharmacology 39:172–180.
    OpenUrlCrossRefPubMed
  180. ↵
    1. Zhong Y,
    2. Dunn PM,
    3. Xiang Z,
    4. Bo X,
    5. Burnstock G
    (1998) Pharmacological and molecular characterization of P2X receptors in rat pelvic ganglion neurons. Br J Pharmacol 125:771–781.
    OpenUrlCrossRefPubMed
  181. ↵
    1. Zhou X,
    2. Galligan JJ
    (1996) P2X purinoceptors in cultured myenteric neurons of guinea-pig small intestine. J Physiol (Lond) 496:719–729.
    OpenUrlPubMed
  182. ↵
    1. Zimmermann H
    (1994) Signalling via ATP in the nervous system. Trends Neurosci 17:420–426.
    OpenUrlCrossRefPubMed
  183. ↵
    1. Zimmermann H,
    2. Braun N
    (1996) Extracellular metabolism of nucleotides in the nervous system. J Auton Pharmacol 16:397–400.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 53 (1)
Pharmacological Reviews
Vol. 53, Issue 1
1 Mar 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
International Union of Pharmacology. XXIV. Current Status of the Nomenclature and Properties of P2X Receptors and Their Subunits
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Review ArticleReview

International Union of Pharmacology. XXIV. Current Status of the Nomenclature and Properties of P2X Receptors and Their Subunits

Baljit S. Khakh, Geoffrey Burnstock, Charles Kennedy, Brian F. King, R. Alan North, Philippe Séguéla, Mark Voigt and Patrick P. A. Humphrey
Pharmacological Reviews March 1, 2001, 53 (1) 107-118;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Review ArticleReview

International Union of Pharmacology. XXIV. Current Status of the Nomenclature and Properties of P2X Receptors and Their Subunits

Baljit S. Khakh, Geoffrey Burnstock, Charles Kennedy, Brian F. King, R. Alan North, Philippe Séguéla, Mark Voigt and Patrick P. A. Humphrey
Pharmacological Reviews March 1, 2001, 53 (1) 107-118;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Overall P2X Subunit Topology
    • III. Electrophysiological Properties of P2X Receptors
    • IV. Functional Properties of Homomeric Receptors
    • V. Functional Properties of Heteromeric Receptors
    • VI. Native Receptors in Whole Tissues
    • VII. Summary
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • International Union of Pharmacology. XLI. Compendium of Voltage-Gated Ion Channels: Potassium Channels
  • International Union of Pharmacology. XLII. Compendium of Voltage-Gated Ion Channels: Cyclic Nucleotide-Modulated Channels
  • International Union of Pharmacology. XLIII. Compendium of Voltage-Gated Ion Channels: Transient Receptor Potential Channels
Show more REVIEW

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics